



TABLE OF CONTENTS FOR TECHNOLOGY TRANSFER AND RESEARCH COMMITTEE

Committee Meeting: 5/8/2013
Austin, Texas

James D. Dannenbaum, Chairman
R. Steven Hicks, Vice Chairman
Alex M. Cranberg
Printice L. Gary
Brenda Pejovich

| | Committee Meeting | Page |
|--|--|-------------|
| Convene | 4:00 p.m. <i>Chairman Dannenbaum</i> | |
| 1. U. T. System: Report on a new investment made by the U. T. Horizon Fund and update on the Fund's portfolio | 4:00 p.m. Report/Discussion <i>Mr. Allinson</i> | 291 |
| 2. U. T. Austin: Report on the Longhorn Startup Program and startup participants Hoot.Me and Lynx Laboratories | 4:05 p.m. Report/Discussion <i>Dr. Robert Metcalfe, Mr. Michael Koetting, and Mr. Chris Slaughter, U. T. Austin</i> | 292 |
| 3. U. T. Health Science Center - San Antonio: Report on Rapamycin Holdings, Inc., a startup company for a drug federally approved to suppress organ rejection | 4:45 p.m. Report/Discussion <i>President Henrich, Mr. Randy Strong, and Mr. Arjun Sanga, U. T. Health Science Center - San Antonio Mr. George Fillis, CEO, Rapamycin Holdings, Inc.</i> | 293 |
| Adjourn | 5:00 p.m. | |

1. **U. T. System: Report on a new investment made by the U. T. Horizon Fund and update on the Fund's portfolio**

REPORT

Mr. Bryan Allinson, Executive Director of Technology Commercialization, will report on an investment of approximately \$336,369 made by the U. T. Horizon Fund into Microtransponder, a startup company that has licensed technology from U. T. Dallas. Consistent with the mission objectives of the U. T. Horizon Fund, the purpose of the investment is to reduce U. T.'s equity dilution. The company has collaborated with health clinicians and academic engineers to develop medical devices to treat neurological diseases.

Mr. Allinson will also provide details on the updated U. T. Horizon Fund portfolio covering originating institution and intellectual property assets licensed.

2. U. T. Austin: Report on the Longhorn Startup Program and startup participants Hoot.Me and Lynx Laboratories

REPORT

Dr. Robert Metcalfe, U. T. Austin Professor of Innovation, will report on the Longhorn Startup Program, a program with multiple tracks aimed at fostering interdisciplinary startup innovation. The Longhorn Startup Seminar is an interdisciplinary speaker series for students interested in starting companies. Startups from the Longhorn Startup Lab are reviewed, and students may participate in numerous networking events. The Longhorn Startup Lab advances ongoing student startup teams with mentoring by successful Austin entrepreneurs. Each semester ends with a Longhorn Startup Demo Day at which several hundred Austin founders gather to network and hear pitches by Lab startups.

The Longhorn Startup Camp is jointly run by the Longhorn Startup Program and the Austin Technology Incubator. The Camp, which encourages student entrepreneurship and collaboration among startups at the University, is currently incubating approximately 40 faculty and student startups and about 250 entrepreneurs in a 30,000-square-foot space in the U. T. Administration Building at 1616 Guadalupe Street.

The monthly Longhorn Startup Studio provides U. T. Austin professors one-on-one guidance in technology commercialization from the Longhorn Startup Program team. Studios are jointly sponsored by U. T. Austin's Office of Technology Commercialization, Austin Technology Incubator, Texas Venture Labs, and the Austin Chamber of Commerce.

Two presentations on new startups participating in the 2012-2013 Longhorn Startup Program will be made at the meeting:

- Mr. Michael Koetting, a U. T. Austin business student with a Management and Information Systems (MIS) minor, will discuss Hoot.Me, which is on a mission to keep learning personal no matter the class size. The concept is that every question is worth asking and that everyone has the potential to teach others by sharing knowledge and collaborating. Through massive open online courses (MOOC), technology is enabling bigger classes than ever before. However, the challenge is that this new scale leads to impersonal class experiences. Being a mere number in a sea of students can be daunting, so Mr. Koetting started Hoot.Me as a free resource for students to get their questions answered by other classmates and teachers. Today, over 30,000 questions and answers have crossed the platform in classes around the world.
- Mr. Chris Slaughter, a U. T. Austin Graduate Research Assistant for the Laboratory for Information and Network Communications, will discuss Lynx Laboratories, which focuses on 3D structural capture and next-generation photography. The team has over 20 years of combined experience in machine learning, resulting in hundreds of publications and a few patents. The company has received prestigious awards, including first place in Idea2Product Global, a global technology competition, and first place in the Idea2Product U. T. Austin Competition. The company was named a 2012 Dell Innovator and is funded by support from the National Science Foundation (NSF) Small Business Innovation Research program.

3. **U. T. Health Science Center - San Antonio: Report on Rapamycin Holdings, Inc., a startup company for a drug federally approved to suppress organ rejection**

REPORT

The following individuals will present a report on Rapamycin Holdings, Inc., a U. T. Health Science Center - San Antonio startup company for a drug federally approved to suppress organ rejection, and its underlying research and commercialization efforts:

- President Henrich
- Dr. Randy Strong, Professor of Pharmacology in the Barshop Institute for Aging and Longevity Studies, U. T. Health Science Center - San Antonio
- Mr. Arjun Sanga, Assistant Vice President of Technology Transfer and Executive Director of South Texas Technology Management, U. T. Health Science Center - San Antonio
- Mr. George Fillis, CEO of Rapamycin Holdings, Inc.

Rapamycin Holdings licenses rapamycin-related intellectual property developed at U. T. Health Science Center - San Antonio. Rapamycin continues to be studied for its potential to slow the aging process and its efficacy in treating age-related diseases such as Alzheimer's and cancer. The U. T. Horizon Fund is investing \$250,000 in Rapamycin Holdings' seed financing under the Existing Ventures funding program.

Science magazine called Rapamycin Holdings' underlying 2009 study one of the 10 scientific breakthroughs of that year. The rapamycin drug is also being studied to reduce other age-related pathologies such as Parkinson's disease (toxin-induced and genetic models), Huntington's disease, atherosclerosis, diabetic nephropathy, and intestinal adenomatous polyps.